Previous 10 | Next 10 |
SEATTLE, Dec. 01, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that patient dosing has begun in ACT-AD , a Pha...
Athira Pharma (ATHA): Q3 GAAP EPS of -$1.12.Cash, cash equivalents and investments of $259.9MPress Release For further details see: Athira Pharma reports Q3 results
- LIFT-AD clinical trial evaluating ATH-1017, a once-daily investigational drug for the treatment of mild-to-moderate Alzheimer’s disease, actively enrolling - Strong cash, cash equivalents and investments balance of $259.9 million as of September 30, 2020 SEATTLE...
SEATTLE, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and stop neurodegeneration, today announced that Dr. Leen Kawas, President and Chief Executive ...
Gainers: Biogen (BIIB) +40%.Cassava Sciences (SAVA) +26%.Athira Pharma (ATHA) +25%.Digirad (DRAD) +22%.Super Micro Computer (SMCI) +21%.Caesarstone (CSTE) +19%.XPeng (XPEV) +19%.Prothena (PRTA) +18%.TravelCenters of America (TA) +18%.Supernus Pharmaceuticals (SUPN) +18%.Losers: Repr...
- Expert neuropsych iatric clinician to discuss the testing method and its correlation to clinical results - Event to feature an in - clinic demonstration of P300 testing - Webcast to be held on Wednesday, Oct. ...
Five biotechs, two medical device makers, a solar panel mounting manufacturer, and a Chinese retailer are scheduled to raise $2.0 billion in the week ahead. Several companies could join the IPO calendar early in the week, including McAfee and Datto Holding. Street research is expe...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week aheadBig banks will lead off the Q3 earnings season next week with investors likely to see more surprises than normal due to t...
Tracking insider purchases is an overlooked but very informative strategy. It can provide undervalued stocks in the market and can make assumptions for future market returns. September's number of insider purchases was close to the historical average, indicating that insiders are not ...
Lumen Bioscience Announces Appointment of Dr. Mark Litton to Board of Directors PR Newswire SEATTLE, Oct. 8, 2020 SEATTLE , Oct. 8, 2020 /PRNewswire/ -- Lumen Bioscience , a clinical-stage biopharmaceutical company developing biologic drugs for highly pr...
News, Short Squeeze, Breakout and More Instantly...
Reporting of Topline Results Targeted by End of Third Quarter 2024 Results to be presented in oral presentation at Clinical Trials on Alzheimer’s Disease (CTAD) on October 29, 2024, in Madrid, Spain BOTHELL, Wash., July 09, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc (N...
Company to provide overview of Phase 2/3 LIFT-AD clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease (AD); LIFT-AD topline data expected in second half of 2024 Two key opinion leaders will discuss ongoing unmet medical need and LIFT-AD’s primary endpoint...
BOTHELL, Wash., June 11, 2024 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ: ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced that it has completed the first cohort of healthy ...